APAC Liver Disease Treatment Market

APAC Liver Disease Treatment Market Size (2023 to 2028)

The size of the Liver Disease Treatment Market in the Asia Pacific is expected to reach USD 3.04 billion by 2028 from USD 1.69 billion in 2023, growing at a CAGR of 12.51% during the forecast period.

APAC's liver disease treatment market is predicted to be driven by factors such as the growing R&D investment, disorganized lifestyle, growing public awareness, the aging population, and unmet demands for liver cancer treatment. As a result of the surge in alcohol consumption, liver cirrhosis is on the rise. According to the World Health Organization, alcohol intake leads to liver cirrhosis in 20% to 50% of people. In addition, obesity has increased the risk of non-alcoholic fatty liver disease, characterized by fat accumulation in the liver. There have been more obese people since 1980.

Due to the increasing prevalence of liver disorders in Asia-Pacific, governments and non-profit organizations play a growing role in raising awareness about liver disorders. As a result, these organizations are dedicated to raising awareness about liver disorders and providing funding for research and development into the prevention, treatment, and cure of liver diseases.

Various medication approvals and the commercialization of numerous anticipated pipeline pharmaceuticals are also projected to boost the market's growth.

With the rising frequency of liver illnesses, liver disease treatment has changed quickly. As a result, several treatment alternatives are available on the market, most of which aim to avoid the course of liver disease and reduce the risk of liver morbidity and death. Furthermore, regional market growth is likely to be fuelled by rising patient awareness and the release of innovative products that address unmet medical requirements throughout the forecast period.

There is fierce competition from alternative medicine (herbal, natural medicine) and side-effects caused by the product (fatigue, fever, and depression). In addition, APAC Liver Disease Treatment market growth is also hindered by the high cost of the drugs.

This research report on the APAC liver disease treatment market has been segmented and sub-segmented into the following categories:

By Treatment Modality:

• Antiviral
• Vaccines
• Chemotherapy
• Immunosuppressive Agents
• Corticosteroids

By Disease Type:

• Hepatitis
• Non-Alcoholic Fatty Liver Disease
• Alcohol-Induced
• Liver Cancer

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, APAC is one of the most lucrative regional markets in the global market. Liver disease can be life-threatening since it can lead to various acute and chronic illnesses (hepatitis, non-alcoholic fatty liver disease, liver cancer, liver tumor, and liver cirrhosis, among others). Nausea, exhaustion, diarrhea, jaundice, bloated belly, and mental confusion are the first signs of liver impairment. Therefore, Asia-Pacific is the fastest-growing market for Liver Disease Treatment Drugs. According to a recent survey, Hepatitis affects 7% of the population in China, with many people in danger of developing chronic liver cancer and cirrhosis. Non-Alcoholic Fatty Liver Disease is also a problem.

Japan is stimulating market expansion because of approved government actions linked to drug cost adjustment and new pharmaceuticals for liver disease treatments. The variables mentioned above contribute to the region's market expansion. In addition, the market demand is fuelled by increased healthcare infrastructure requirements, rising hepatitis, and hepatocellular cancer.

Around 1 million people in India have recently been diagnosed with liver cirrhosis. The rise in the number of obese and diabetic people doubles market growth. The liver disease treatment industry in the area is being fuelled by a changing lifestyle and increased economic prosperity.

KEY MARKET PLAYERS:

Companies playing a significant role in the Asia Pacific liver disease treatment market profiled in the report are Gilead Science Inc. (U.S.), Pfizer Inc. (U.S.), Merck & Co. (U.S.), Johnson & Johnson (U.S.), Novartis (Switzerland), Roche (Switzerland), Sanofi-Aventis (France), Abbott Laboratories (U.S.), Bayer Schering AG (Germany) and AstraZeneca (United Kingdom).